536 related articles for article (PubMed ID: 15452128)
1. Altered amyloid-beta metabolism and deposition in genomic-based beta-secretase transgenic mice.
Chiocco MJ; Kulnane LS; Younkin L; Younkin S; Evin G; Lamb BT
J Biol Chem; 2004 Dec; 279(50):52535-42. PubMed ID: 15452128
[TBL] [Abstract][Full Text] [Related]
2. Spatial and temporal control of age-related APP processing in genomic-based beta-secretase transgenic mice.
Chiocco MJ; Lamb BT
Neurobiol Aging; 2007 Jan; 28(1):75-84. PubMed ID: 16387391
[TBL] [Abstract][Full Text] [Related]
3. Effects of Folic Acid on Secretases Involved in Aβ Deposition in APP/PS1 Mice.
Tian T; Bai D; Li W; Huang GW; Liu H
Nutrients; 2016 Sep; 8(9):. PubMed ID: 27618097
[TBL] [Abstract][Full Text] [Related]
4. The beta-secretase, BACE: a prime drug target for Alzheimer's disease.
Vassar R
J Mol Neurosci; 2001 Oct; 17(2):157-70. PubMed ID: 11816789
[TBL] [Abstract][Full Text] [Related]
5. Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.
Johnson ECB; Ho K; Yu GQ; Das M; Sanchez PE; Djukic B; Lopez I; Yu X; Gill M; Zhang W; Paz JT; Palop JJ; Mucke L
Mol Neurodegener; 2020 Sep; 15(1):53. PubMed ID: 32921309
[TBL] [Abstract][Full Text] [Related]
6. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.
Velliquette RA; O'Connor T; Vassar R
J Neurosci; 2005 Nov; 25(47):10874-83. PubMed ID: 16306400
[TBL] [Abstract][Full Text] [Related]
7. BACE1: the beta-secretase enzyme in Alzheimer's disease.
Vassar R
J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
[TBL] [Abstract][Full Text] [Related]
8. The contribution of activated astrocytes to Aβ production: implications for Alzheimer's disease pathogenesis.
Zhao J; O'Connor T; Vassar R
J Neuroinflammation; 2011 Nov; 8():150. PubMed ID: 22047170
[TBL] [Abstract][Full Text] [Related]
9. NFkappaB-dependent control of BACE1 promoter transactivation by Abeta42.
Buggia-Prevot V; Sevalle J; Rossner S; Checler F
J Biol Chem; 2008 Apr; 283(15):10037-47. PubMed ID: 18263584
[TBL] [Abstract][Full Text] [Related]
10. Reduction of β-amyloid accumulation by reticulon 3 in transgenic mice.
Araki W; Oda A; Motoki K; Hattori K; Itoh M; Yuasa S; Konishi Y; Shin RW; Tamaoka A; Ogino K
Curr Alzheimer Res; 2013 Feb; 10(2):135-42. PubMed ID: 22742855
[TBL] [Abstract][Full Text] [Related]
11. The Swedish APP mutation alters the effect of genetically reduced BACE1 expression on the APP processing.
Rabe S; Reichwald J; Ammaturo D; de Strooper B; Saftig P; Neumann U; Staufenbiel M
J Neurochem; 2011 Oct; 119(1):231-9. PubMed ID: 21812781
[TBL] [Abstract][Full Text] [Related]
12. Pro-oxidant diet enhances β/γ secretase-mediated APP processing in APP/PS1 transgenic mice.
Choudhry F; Howlett DR; Richardson JC; Francis PT; Williams RJ
Neurobiol Aging; 2012 May; 33(5):960-8. PubMed ID: 20724034
[TBL] [Abstract][Full Text] [Related]
13. BACE1 elevation is involved in amyloid plaque development in the triple transgenic model of Alzheimer's disease: differential Aβ antibody labeling of early-onset axon terminal pathology.
Cai Y; Zhang XM; Macklin LN; Cai H; Luo XG; Oddo S; Laferla FM; Struble RG; Rose GM; Patrylo PR; Yan XX
Neurotox Res; 2012 Feb; 21(2):160-74. PubMed ID: 21725719
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.
Ly PT; Wu Y; Zou H; Wang R; Zhou W; Kinoshita A; Zhang M; Yang Y; Cai F; Woodgett J; Song W
J Clin Invest; 2013 Jan; 123(1):224-35. PubMed ID: 23202730
[TBL] [Abstract][Full Text] [Related]
15. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
[TBL] [Abstract][Full Text] [Related]
16. Beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity.
Shi XP; Tugusheva K; Bruce JE; Lucka A; Wu GX; Chen-Dodson E; Price E; Li Y; Xu M; Huang Q; Sardana MK; Hazuda DJ
J Biol Chem; 2003 Jun; 278(23):21286-94. PubMed ID: 12665519
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's β-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of β-amyloid.
Chen Y; Huang X; Zhang YW; Rockenstein E; Bu G; Golde TE; Masliah E; Xu H
J Neurosci; 2012 Aug; 32(33):11390-5. PubMed ID: 22895721
[TBL] [Abstract][Full Text] [Related]
18. PAR-4 is involved in regulation of beta-secretase cleavage of the Alzheimer amyloid precursor protein.
Xie J; Guo Q
J Biol Chem; 2005 Apr; 280(14):13824-32. PubMed ID: 15671026
[TBL] [Abstract][Full Text] [Related]
19. GEPT extract reduces Abeta deposition by regulating the balance between production and degradation of Abeta in APPV717I transgenic mice.
Tian J; Shi J; Zhang L; Yin J; Hu Q; Xu Y; Sheng S; Wang P; Ren Y; Wang R; Wang Y
Curr Alzheimer Res; 2009 Apr; 6(2):118-31. PubMed ID: 19355846
[TBL] [Abstract][Full Text] [Related]
20. The proteins BACE1 and BACE2 and beta-secretase activity in normal and Alzheimer's disease brain.
Stockley JH; O'Neill C
Biochem Soc Trans; 2007 Jun; 35(Pt 3):574-6. PubMed ID: 17511655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
